OSE Pharma SA

OSE Immunotherapeutics SA is a clinical-stage biotechnology company that develops immunotherapies in immune-oncology and immune-inflammation in France and internationally. Its pipeline includes Tedopi in Phase III for non-small cell lung cancer and Phase II for pancreatic and ovarian cancer; OSE-279 in Phase I/II for advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody in Phase II for ulcerative colitis and Sjögren's syndrome; and FR104 in Phase I for rheumatoid arthritis. The company is also developing BI 765063 in Phase I for solid tumors, ABBV-230, an agonist antibody against ChemR23 for chronic inflammation, CLEC-1, a therapeutic target in immune-oncology with identified monoclonal antibody antagonists, and BiCKI, a bispecific checkpoint inhibitor technology targeting the PD1 receptor and other targets. It has collaborations with GERCOR, ARCAGY-GINECO, Foundation FoRT, Nantes University Hospital, Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. Formerly OSE Pharma SA, it changed its name to OSE Immunotherapeutics SA in May 2016, was founded in 2012, and is headquartered in Nantes, France.

Biotech & Genomic Medicine▲

OSE Immunotherapeutics Welcomes First Patient Dosed in Phase 2 RENGEVITY-201 Trial

OSE Immunotherapeutics announced that its licensee Veloxis Pharmaceuticals has dosed the first patient in the Phase 2 RENGEVITY-201 trial evaluating pegrizeprument (VEL-101) for the prevention of organ rejection in kidney transplant recipients. Pegrizeprument, an investigational immunomodulatory antibody fragment originally developed by OSE and licensed to Veloxis in 2021, is being developed for all transplant indications, with Veloxis responsible for worldwide development, manufacturing, and commercialization. The trial is part of a broader program that has already received Orphan Drug Designation from the U.S. Food and Drug Administration for liver and heart transplant indications in December 2025 and March 2026, respectively.

OSE.PA ▲

Biotech & Genomic Medicine

Yahoo Finance·9dRead more →